Topical Doxepin for Radiation-induced Dermatitis
Launched by ISFAHAN UNIVERSITY OF MEDICAL SCIENCES · May 14, 2015
Trial Information
Current as of May 25, 2025
Unknown status
Keywords
ClinConnect Summary
The patients who have undergone breast surgery and require radiotherapy and fulfill the inclusion criteria of the study will be entered the study. All the patients will be treated by 3D conformal radiation therapy using CT -based treatment planning and multi leaf linear accelerators. The patients will be treated by conventional fractionation regimens to a total dose of 5000 cGy (25 fractions of 200 cGy, 5 days per week). Every week the patients will be visited by an experienced radiation oncologist and the skin reaction will be determined and recorded according to RTOG Acute Radiation Morbi...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Female with a diagnosis of, breast adenocarcinoma and be referred for post-operative radiotherapy with or without concurrent chemotherapy and with or without mastectomy
- • Participants must not be pregnant.
- • Participants treated with a total dose of 5000 cGy (25 fractions of 200 cGy, 5 days per week
- Exclusion Criteria:
- • Patients who are not eligible
- • The presence of skin diseases in the radiation area
- • Patients have constipation, xerostomia, blurred vision, urinary retention
- • Hypersensitivity to doxepin
About Isfahan University Of Medical Sciences
Isfahan University of Medical Sciences is a leading academic institution in Iran, dedicated to advancing healthcare through innovative research and education. With a strong emphasis on clinical trials, the university plays a critical role in developing new medical treatments and improving patient outcomes. Its research initiatives are supported by a diverse team of professionals, including physicians, scientists, and healthcare practitioners, who collaborate to address pressing health challenges. The university is committed to adhering to the highest ethical standards and regulatory guidelines, ensuring the integrity and reliability of its clinical research endeavors. Through its comprehensive approach, Isfahan University of Medical Sciences aims to contribute significantly to the global medical community and enhance public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Isfahan, , Iran, Islamic Republic Of
Patients applied
Trial Officials
Golnaz Vaseghi, Ph.D
Principal Investigator
Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
Alireza Amouheidari, MD
Principal Investigator
Head, Department of Radiation Oncology,Isfahan Milad Hospital, Isfahan,Iran
Laleh Shariati, Ph.D
Principal Investigator
Isfahan University of Medical Sciences
Shaghayegh Shaghayegh Haghjoo-Javanmard, Ph.D
Study Director
Applied Physiology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
Hajar Naji, M.S
Study Chair
Applied Physiology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials